• Explore /
  • Poster
  • / Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.

Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.

Abstract Video & Slides Poster

Authors

null

Carolyn Muller

University of New Mexico, Albuquerque, NM

Carolyn Muller , Ursa Abigail Brown-Glaberman , Marya F. Chaney , Tina Garyantes , Patricia LoRusso , Jennifer Leigh McQuade , Alain C. Mita , Monica M. Mita , Christopher Natale , Marlana Orloff , Kyriakos P. Papadopoulos , Takami Sato , Emrullah Yilmaz , Jordi Rodon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT04130516

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3084)

DOI

10.1200/JCO.2021.39.15_suppl.3084

Abstract #

3084

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Judy S. Wang

First Author: Mohamed Shanshal

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

First Author: Jing Huang

First Author: Jin Li